DiaMedica rises on FDA fast track tag for stroke therapy

DiaMedica Therapeutics

30/09/2021 17:10

** Shares of drug developer  DMAC.O  rise 4.1% to $4.21
    ** DMAC says the U.S. FDA has granted Fast Track designation
to its lead drug candidate, DM199, for the treatment of acute
ischemic stroke, which is caused by blood clots in arteries
 urn:newsml:reuters.com:*:nBwbtMS0Ma
    ** The tag is intended to speed up review of experimental
treatments for serious or life-threatening conditions
    ** DM199 is intended to treat acute ischemic stroke in cases
where therapy with a clot-dissolving medicine called tissue
plasminogen activator or a minimally invasive procedure for
blood clot removal are considered medically inappropriate - co  
 
    ** The drug candidate is also being tested to treat chronic
kidney disease 
    ** Stock down 58.5% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))